Eplerenone for chronic central serous chorioretinopathy

Affiliations

¹ Department of Ophthalmology, University Vita-Salute, IRCCS Ospedale San Raffaele, Milan 20132, Italy.
² Department of Ophthalmology, University Vita-Salute, IRCCS Ospedale San Raffaele, Milan 20132, Italy. Electronic address: querques.giuseppe@hsr.it.

Comment

Riccardo Sacconi et al. Lancet. 2020.

. 2020 Nov 14;396(10262):1556.

doi: 10.1016/S0140-6736(20)31610-X.

¹ Department of Ophthalmology, University Vita-Salute, IRCCS Ospedale San Raffaele, Milan 20132, Italy.
² Department of Ophthalmology, University Vita-Salute, IRCCS Ospedale San Raffaele, Milan 20132, Italy. Electronic address: querques.giuseppe@hsr.it.

No abstract available

Comment in

Eplerenone for chronic central serous chorioretinopathy - Authors' reply.
Lotery A, O'Connell A, Harris RA, Sivaprasad S, Reeves BC. Lotery A, et al. Lancet. 2020 Nov 14;396(10262):1557-1558. doi: 10.1016/S0140-6736(20)32321-7. Lancet. 2020. PMID: 33189170 No abstract available.

Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months (VICI): a randomised, double-blind, placebo-controlled trial.
Lotery A, Sivaprasad S, O'Connell A, Harris RA, Culliford L, Ellis L, Cree A, Madhusudhan S, Behar-Cohen F, Chakravarthy U, Peto T, Rogers CA, Reeves BC; VICI trial investigators. Lotery A, et al. Lancet. 2020 Jan 25;395(10220):294-303. doi: 10.1016/S0140-6736(19)32981-2. Lancet. 2020. PMID: 31982075 Clinical Trial.